SCHEMBL4679653

SCHEMBL4679653

O=C(Cc1csc(S(=O)(=O)c2ccccc2)c1)C(=O)c1nn[nH]n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.37
NCEH1 Q6PIU2 1/20 0.37
ERCC5 P28715 1/20 0.34
FEN1 P39748 1/20 0.34
MMEL1 Q495T6 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MMP8 P22894 2/20 0.32
MMP3 P08254 1/20 0.32
PTGDR2 Q9Y5Y4 2/20 0.32
CYP2C8 P10632 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675060 0.90 CXCR3 (0.36) ALDH1A1CYP2C19
SCHEMBL4675172 0.90 CXCR3 (0.34) PTGDR2CYP2C8CYP2C9CYP2C19KEAP1
SCHEMBL4674871 0.83 LOXL2 (0.33) ALDH1A1MMP8MMP3LOXPRMT1
SCHEMBL4675587 0.81 LOX (0.39) CES1NCEH1ERCC5FEN1ALDH1A1
SCHEMBL4679291 0.80 LOX (0.49) CES1NCEH1LOX
SCHEMBL4674296 0.80 RPS6KB2 (0.40) CES1NCEH1ERCC5FEN1MMEL1
SCHEMBL4673217 0.79 CES1 (0.38) CES1NCEH1ERCC5FEN1MMEL1
SCHEMBL4673888 0.79 LTB4R (0.44) CES1NCEH1ERCC5FEN1MMEL1
SCHEMBL4672426 0.78 CES1 (0.37) CES1NCEH1ERCC5FEN1MMEL1
SCHEMBL4674556 0.78 LOXL2 (0.41) CES1NCEH1ERCC5FEN1MMEL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885ERCC5 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.